NEWS & EVENTS
- Sort By:
Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study
Ustekinumab is a monoclonal antibody targeting interleukin (IL)-12 and IL-23 and is approved for the treatment of plaque psoriasis, psoriatic arthritis, and Crohn’s disease. IL-12 and IL-23 have been implicated in systemic lupus erythematosus. We aimed to assess the efficacy and safety of ustekinumab for the treatment of systemic lupus erythematosus in patients with moderate-to-severe disease activity despite conventional treatment.
First Latin American clinical practice guidelines for the treatment of systemic lupus erythematosus: Latin American Group for the Study of Lupus (GLADEL, Grupo Latino Americano de Estudio del Lupus)–Pan-American League of Associations of Rheumatology (PANLAR)
Systemic lupus erythematosus (SLE) is a complex multisystemic autoimmune disease resulting, oftentimes, in irreversible damage, diminished quality of life and reduced life expectancy.1–3 Genetic and environmental factors play important roles in its pathogenesis.4–8 Disease manifestations and severity vary according to the patients’ racial/ethnic background and socioeconomic status (SES).
Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial
Systemic lupus erythematosus is a multisystem, chronic autoimmune disease characterised by the presence of antibodies directed at self-antigens, and broad immune dysregulation. It is believed that abnormalities of both the innate and adaptive arms of the immune system, interconnected by a positive feedback loop, contribute to disease pathogenesis.
The Evelyn V. Hess Award is given annually to recognize the exceptional contributions of a clinical or basic researcher whose body of work has advanced the understanding of the science of lupus treatment.
At a reception during the 2018 ACR/ARHP Annual Meeting in Chicago, the Lupus Foundation of America presented the Evelyn V. Hess Award to Michelle Petri, MD, MPH, the director of the Hopkins Lupus Center and co-director of the Hopkins Lupus Pregnancy Center. She was honored for her extensive contributions and impact on the field of lupus over the past 30 years…
The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults
SLE (or lupus for short) is a multisystem, autoimmune disease, involving complex pathogenetic mechanisms that can present at any age. It most commonly presents in women in the reproductive age group, although lupus is increasingly recognized after the age of 40 years, particularly in Europeans…
Dr Marwan Bukhari and Dr John Hanly, Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, Canada, talk about his paper on the frequency and outcome of lupus nephritis in a prospective SLE inception cohort. In the SLICC inception cohort study, 38% percent of patients developed lupus nephritis within the first 5 years of disease, with 10% of these developing end stage renal disease at 10 year follow-up.